Please login to the form below

biopharma

This page shows the latest biopharma news and features for those working in and with pharma, biotech and healthcare.

$11.4bn takeover of Array Biopharma last year, particularly for its potential as a colorectal cancer treatment.

Lundbeck drops Parkinson’s drug acquired in €905m deal

It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from
AstraZeneca forms $2bn gene silencing pact with Silence Tx

AZ’s head of biopharma R&D Mene Pangalos said the alliance “adds an exciting new modality, siRNA, into our drug discovery toolbox.”.
AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance

levels. Looking to join Roche and a number of other pharma companies is Can-Fite Biopharma, which has submitted its anti-inflammatory drug piclidenoson for a compassionate use programme to treat
Bayer signs €250m pact with India’s Curadev for STING drugs

More than a dozen biopharma companies have been looking at STING agonists as potential treatments for cancer by switching on the inflammatory response against tumour cells, including Merck &Co and Novartis.
FDA green lights study of phage-based drug for resistant infections

APT is one of a number of biopharma companies trying to harness the bacteria-killing properties of phages to offer an alternative to antibacterial drugs.

More from news
Approximately 17 fully matching, plus 438 partially matching documents found.

AI and genomics: a revolution in drug discovery and development

The omics approach could also help biotech companies attract acquisitive biopharma companies.
COVID-19: the race to find a vaccine

How biopharma is working to bring an end to the pandemic.
Biopharma and orphan drugs

Nevertheless, the consensus is that EMA and FDA programmes designed to encourage biopharma to develop medicines for smaller patient populations – primarily the orphan designation – are working. ... While there are differences in the specific
As COVID-19 takes over the world, biopharma fights back

Biopharma companies across the world unite in the race to find an effective COVID-19 treatment.
Pharma funding and M&A in 2020

and biopharma firms.

More from intelligence
Approximately 1 fully matching, plus 82 partially matching documents found.

New hires at Crescendo, Healx and Galecto

Prior to joining Healx, he worked as CMO at Aparito and as therapeutic area head of orphan drugs at Mereo BioPharma.
New hires at FibroGen, Saniona and Turbine

Jenkins is a biopharma thought leader with over 25 years of industry experience, whose leadership roles have included global head of R&D at Merck Serono, and several senior positions at
New hires at Bristol-Myers Squibb, Acceleron and FerGene

While at Ipsen, Meek led a growth strategy of financial results and pipeline advancement and transformed the company into a global biopharma leader.
New faces at Healthware Group and HRW

ups, biopharma companies, technology firms and others. She will be based in New York City, US.
Health comms agency emotive hires new cell and gene therapy leader

An expert in cell and gene therapies, Dr Ferrari joins emotive following 20 years in research as well as holding medical affairs and commercial roles in biopharma and diagnostics.

More from appointments
Approximately 8 fully matching, plus 142 partially matching documents found.

Can patient insights improve clinical trial recruitment strategies?

According to The Patient Gap, a report developed from the analysis of three proprietary studies, 6% of healthcare clients hold the belief that biopharma companies are on their side.
The role of medical affairs in positive and appropriate engagement with patient advocacy groups

Biopharma recognises the importance of positive engagement and partnership with patient groups. ... A question remains around how, and which part of a biopharma organisation should be involved in building patient group relationships.
The changing face of pharma in the precision era

Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. ... While medical affairs teams are usually focused on developing scientific communications about a product or service for
Precision medicine from concept to clinic

Nancy Brandt explains how a top biopharma company is transforming internally to ensure it sits at the forefront of innovation.
JPA Health

The agency provides services to clients across the health sector, including: biopharma, medtech, and non-profit organisations.